SG11201503505QA - Novel orally bioavailable breathing control modulating compounds, and methods of using same - Google Patents
Novel orally bioavailable breathing control modulating compounds, and methods of using sameInfo
- Publication number
- SG11201503505QA SG11201503505QA SG11201503505QA SG11201503505QA SG11201503505QA SG 11201503505Q A SG11201503505Q A SG 11201503505QA SG 11201503505Q A SG11201503505Q A SG 11201503505QA SG 11201503505Q A SG11201503505Q A SG 11201503505QA SG 11201503505Q A SG11201503505Q A SG 11201503505QA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- same
- modulating compounds
- orally bioavailable
- breathing control
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/54—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/54—Three nitrogen atoms
- C07D251/70—Other substituted melamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261726823P | 2012-11-15 | 2012-11-15 | |
US201361783451P | 2013-03-14 | 2013-03-14 | |
PCT/US2013/070160 WO2014078575A2 (en) | 2012-11-15 | 2013-11-14 | Novel orally bioavailable breathing control modulating compounds, and methods of using same |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201503505QA true SG11201503505QA (en) | 2015-06-29 |
Family
ID=50731822
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201503505QA SG11201503505QA (en) | 2012-11-15 | 2013-11-14 | Novel orally bioavailable breathing control modulating compounds, and methods of using same |
Country Status (12)
Country | Link |
---|---|
US (1) | US20150291597A1 (en) |
EP (1) | EP2920155A2 (en) |
JP (1) | JP2015537032A (en) |
KR (1) | KR20150082633A (en) |
CN (1) | CN104918923A (en) |
AU (1) | AU2013344653A1 (en) |
BR (1) | BR112015011213A2 (en) |
CA (1) | CA2891342A1 (en) |
EA (1) | EA201590933A1 (en) |
MX (1) | MX2015006120A (en) |
SG (1) | SG11201503505QA (en) |
WO (1) | WO2014078575A2 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2013267570A1 (en) * | 2012-05-29 | 2014-12-18 | Galleon Pharmaceuticals, Inc. | Novel compounds and compositions for treatment of breathing control disorders or diseases |
US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
US10004749B2 (en) | 2015-07-22 | 2018-06-26 | John Hsu | Composition comprising a therapeutic agent and a respiratory stimulant and methods for the use thereof |
EP3393470B1 (en) | 2015-12-22 | 2021-01-20 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
RU2731179C2 (en) | 2015-12-22 | 2020-08-31 | Зодженикс Интернэшнл Лимитед | Fenfluramine compositions and methods for production thereof |
JP2019526544A (en) | 2016-08-24 | 2019-09-19 | ゾゲニクス インターナショナル リミテッド | Formulations for inhibiting the formation of 5-HT2B agonists and methods of use thereof |
US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
US11571397B2 (en) | 2018-05-11 | 2023-02-07 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
WO2019241005A1 (en) | 2018-06-14 | 2019-12-19 | Zogenix International Limited | Compositions and methods for treating respiratory depression with fenfluramine |
US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
US20230140606A1 (en) * | 2021-11-02 | 2023-05-04 | Enalare Therapeutics Inc. | Methods of treating respiratory depression modulated by a non-opioid agent |
WO2023129502A1 (en) * | 2021-12-27 | 2023-07-06 | Enalare Therapeutics Inc. | Respiratory stimulant parenteral formulations |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9106170D0 (en) * | 1991-03-22 | 1991-05-08 | Jarman Michael | New compounds for use in the treatment of cancer |
JP5249042B2 (en) * | 2006-10-30 | 2013-07-31 | 新日鉄住金化学株式会社 | Proton conducting compound and proton conducting polymer |
DE102007025451B4 (en) * | 2007-05-31 | 2013-03-28 | Ami Agrolinz Melamine International Gmbh | triazine derivatives |
SG10201601507YA (en) * | 2010-11-29 | 2016-04-28 | Galleon Pharmaceuticals Inc | Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases |
WO2012166909A1 (en) * | 2011-06-03 | 2012-12-06 | Galleon Pharmaceuticals, Inc. | Compositions and methods for treating breathing control disorders or diseases |
-
2013
- 2013-11-14 EP EP13854758.3A patent/EP2920155A2/en not_active Withdrawn
- 2013-11-14 EA EA201590933A patent/EA201590933A1/en unknown
- 2013-11-14 SG SG11201503505QA patent/SG11201503505QA/en unknown
- 2013-11-14 WO PCT/US2013/070160 patent/WO2014078575A2/en active Application Filing
- 2013-11-14 US US14/442,777 patent/US20150291597A1/en not_active Abandoned
- 2013-11-14 CA CA2891342A patent/CA2891342A1/en not_active Abandoned
- 2013-11-14 AU AU2013344653A patent/AU2013344653A1/en not_active Abandoned
- 2013-11-14 KR KR1020157015724A patent/KR20150082633A/en not_active Application Discontinuation
- 2013-11-14 JP JP2015542789A patent/JP2015537032A/en active Pending
- 2013-11-14 BR BR112015011213A patent/BR112015011213A2/en not_active IP Right Cessation
- 2013-11-14 MX MX2015006120A patent/MX2015006120A/en unknown
- 2013-11-14 CN CN201380070474.7A patent/CN104918923A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN104918923A (en) | 2015-09-16 |
BR112015011213A2 (en) | 2017-08-29 |
US20150291597A1 (en) | 2015-10-15 |
CA2891342A1 (en) | 2014-05-22 |
WO2014078575A3 (en) | 2014-10-16 |
AU2013344653A1 (en) | 2015-05-21 |
KR20150082633A (en) | 2015-07-15 |
MX2015006120A (en) | 2016-02-05 |
WO2014078575A2 (en) | 2014-05-22 |
EA201590933A1 (en) | 2015-11-30 |
EP2920155A2 (en) | 2015-09-23 |
JP2015537032A (en) | 2015-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201503505QA (en) | Novel orally bioavailable breathing control modulating compounds, and methods of using same | |
GB2500583B (en) | Interference control | |
WO2013158208A9 (en) | Multi-modal synchronization therapy | |
EP2922615A4 (en) | Control of mercury emissions | |
SG11201502932TA (en) | Compounds and methods for the production of suckerin and uses thereof | |
EP2935226A4 (en) | Heteroaryl compounds and uses thereof | |
EP2867209A4 (en) | Compounds and therapeutic uses thereof | |
HK1202991A1 (en) | Control transformer | |
ZA201504167B (en) | Processes for the preparation of 4-amino-3-halo-6- (substituted)picolinates and 4-amino-5-fluoro-3-halo-6- (substituted)picolinates | |
HK1219234A1 (en) | Novel breathing control modulating compounds, and methods of using same | |
PL2882708T3 (en) | New compounds and uses thereof | |
TWI562792B (en) | Breathing apparatus | |
EP2804612A4 (en) | Therapeutic uses of tetrachlorodecaoxygen (tcdo) | |
GB2519926B (en) | Breathing apparatus | |
HUE036419T2 (en) | Treatment of respiratory depression | |
GB201203391D0 (en) | Medico-surgical assemblies | |
AU2012904536A0 (en) | Improved breathing apparatus | |
AU2012903663A0 (en) | Improved breathing apparatus | |
AU2012902308A0 (en) | Breathing Means | |
GB2499018B (en) | Breathing mask | |
AU2012904991A0 (en) | Therapeutic Compounds and Uses Thereof | |
HK1170109A2 (en) | Red cheque packet | |
GB201216381D0 (en) | New compounds and medical uses | |
GB201208970D0 (en) | New compounds and medical uses | |
GB201203388D0 (en) | Medico-surgical assemblies |